The endocannabinoids synthesis and CB1 and CB2 hepatic expression have been demonstrated to be increased in several conditions characterized by chronic liver damage, such as alcoholic and non-alcoholic fatty liver, viral hepatitis and fibrosis [18–20, 50, 51]. This evidence concerns the gene CNR2 and animal viral hepatitis.